Grantee Research Project Results
2013 Progress Report: Integration of Filtration and Advanced Oxidation: Development of a Membrane Liquid-Phase Plasma Reactor
EPA Grant Number: R835332Title: Integration of Filtration and Advanced Oxidation: Development of a Membrane Liquid-Phase Plasma Reactor
Investigators: Bellona, Christopher , Holsen, Thomas M. , Mededovic Thagard, Selma , Dickenson, Eric
Current Investigators: Bellona, Christopher , Holsen, Thomas M. , Dickenson, Eric , Mededovic Thagard, Selma
Institution: Clarkson University , Southern Nevada Water Authority
EPA Project Officer: Packard, Benjamin H
Project Period: August 16, 2012 through August 15, 2016 (Extended to August 15, 2017)
Project Period Covered by this Report: August 16, 2012 through August 16,2013
Project Amount: $499,779
RFA: Research and Demonstration of Innovative Drinking Water Treatment Technologies in Small Systems (2011) RFA Text | Recipients Lists
Research Category: Drinking Water , Water
Objective:
Engineer, develop and demonstrate an integrated process comprised of membrane technology and electrical discharge plasma generated via a novel reticulated vitreous carbon (RVC) electrode material. The successful development of this process will result in a technology that is scalable, robust, requires minimal chemical input, has a small foot-print, and achieves a finished water quality better than treatment systems that require multiple technologies.
Progress Summary:
Reacts quickly with D2/and DH= | Reacts slowly with D2 and quickly with DH= | Reacts slowly with D2 and OH= | |||
---|---|---|---|---|---|
Compound | Type | Compound | Type | Compound | Type |
Carbamazepine | Pharmaceutical | Diazepam | Pharmaceutical | Chloraceldaad | Regulated DBP |
Sulfamethoxazole | Pharmaceutical | Iopromide | X-raycontranstiagent | Chlorophorm | Regulated DBP |
Trimethoprim | Pharmaceutical | Ibuprofren | Pharmaceutical | TCEP | Flame Reardent |
Caffine | Stimulant | 1,4-dioxaine | Industrial use | PFOA | Industrial Use/GOCL3 |
Fluoxetine | Pharmaceutical | Meprobamate | Pharmaceutical | PFOS | Industrial Use/GOCL3 |
Naproxen | Pharmaceutical | Dilantin | Pharmaceutical | PFHxA | Indsrtrial Use |
Tridosan | Pharmaceutical | DEET | Insecticide | PFHxS | Industrial Use |
Acetaminophen | Pharmaceutical | Primidone | Pharmaceutical | PFBA | Industrial Use |
Tridocarbon | Pharmaceutical | Simazine | Herbicide | PFBS | Industrial Use |
Atenolol | Pharmaceutical | Atrazine | Herbicide | NDMA | DBP,ODCL3 |
Gemfibrozil | Pharmaceutical | MBTE | CCL3 | Sucrose | Artificial Sweetener |
Bisphenol-A | EDC | Muslo ketone | Fragrance | ||
17ß-Estradiol | EDC,ODCL3 | Diatrizoate | X-raycontranstiagent | ||
Trichloronitramethane | DBP | ||||
17-αEthinylestradiol | (chloropicrin) | DBP | |||
Nitrobenzene | EDC,ODCL3 |
Future Activities:
The research team will continue to optimize and engineer the plasma process through controlled experiments with single organic contaminants (Task 2A). Once these experiments are completed, the plasma process will be tested with a mixture containing the contaminants presented in Table 1 at environmentally relevant concentrations (i.e., at the ng/L concentration range). Plasma degradation experiments will be conducted in the presence of reactive species scavengers to elucidate reaction mechanisms (Task 2B). The bench-scale ceramic membrane system will be integrated with the plasma reactor, and several membrane types will be evaluated. The impact of dissolved organic matter on contaminant degradation will be evaluated by spiking organic contaminants into Raquette river water and performing plasma degradation experiments in the absence and presence of the ceramic membrane system (Task 2C).
Journal Articles:
No journal articles submitted with this report: View all 22 publications for this projectProgress and Final Reports:
Original AbstractThe perspectives, information and conclusions conveyed in research project abstracts, progress reports, final reports, journal abstracts and journal publications convey the viewpoints of the principal investigator and may not represent the views and policies of ORD and EPA. Conclusions drawn by the principal investigators have not been reviewed by the Agency.